Bleeding Risk and Outcomes of Patients Undergoing Percutaneous Coronary Intervention Treated with Antiplatelets

Sa'ar Minha, Ron Waksman

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Pharmacological inhibition of platelet activity is associated with improved outcomes in patients undergoing percutaneous coronary intervention (PCI). These merits are hampered by an inherent increased bleeding risk, which in turn, translates into increased mortality risk. This chapter describes the incidence, predictors, and outcome of bleeding events associated with PCI and further describes various means to minimize the risks for this dreadful complication.

Original languageEnglish
Title of host publicationAntiplatelet Therapy in Cardiovascular Disease
PublisherWiley-Blackwell
Pages253-258
Number of pages6
ISBN (Electronic)9781118493984
ISBN (Print)9781118275757
DOIs
StatePublished - 3 Jun 2014
Externally publishedYes

Keywords

  • Antiplatelet therapy
  • Bleeding
  • Mortality
  • Transfusion

Fingerprint

Dive into the research topics of 'Bleeding Risk and Outcomes of Patients Undergoing Percutaneous Coronary Intervention Treated with Antiplatelets'. Together they form a unique fingerprint.

Cite this